Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade
Taysha Gene Therapies (NASDAQ:TSHA) saw its shares rise by 6.9% after Canaccord Genuity upgraded its price target from $14.00 to $17.00. The company also reported stronger-than-expected quarterly earnings and revenue, though insider selling occurred recently. Institutional investors hold a significant portion of its stock.
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00
Canaccord Genuity Group raised its price target for Taysha Gene Therapies (NASDAQ:TSHA) to $17.00 from $14.00, maintaining a "buy" rating with a potential upside of 262.09% from its current price of $4.70. The company recently exceeded quarterly EPS and revenue estimates, though insiders have sold a significant number of shares. Analysts currently have an average "Buy" rating and a target price of $11.64 for Taysha Gene Therapies.
Canaccord raises Taysha Gene Therapies price target on trial progress
Canaccord raised its price target on Taysha Gene Therapies (NASDAQ:TSHA) shares to $17 from $14, maintaining a Buy rating, citing trial progress. The company expects to complete dosing in its REVEAL and ASPIRE trials in Q2 2026 and anticipates updated Part A data for REVEAL, showing 100% milestone gain in patients. Despite a widened net loss in 2025, other firms like Jefferies, Raymond James, and Cantor Fitzgerald have also raised price targets or reiterated positive ratings based on the advancements in Taysha's gene therapy trials.
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Capricorn Fund Managers Ltd has acquired a new stake of 300,000 shares in Taysha Gene Therapies (NASDAQ: TSHA) during the fourth quarter, valued at approximately $1.65 million. This investment comes amidst mixed insider activity, with CFO Kamran Alam and CEO Sean P. Nolan selling a combined 215,757 shares in January. Despite insider sales, analysts maintain a "Buy" rating for Taysha Gene Therapies with a consensus price target of $11.09, following recent positive earnings results.
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation
This article reports that Citizens has reiterated its Market Outperform rating for Taysha Gene Therapies (TSHA). No further details about the reasons for this rating or any financial analysis are provided in the current content.
5 Best Multibagger Penny Stocks to Invest In
This article lists the top 5 multibagger penny stocks, with a focus on Taysha Gene Therapies, Inc. (NASDAQ: TSHA) as the fifth best. Taysha Gene Therapies is highlighted for its progress in developing a gene therapy for Rett syndrome, TSHA-102, which has received positive analyst ratings and FDA clearance for a new trial. The company's financial performance shows an increased net loss in 2025 due to higher research and development expenses, while its core mission is to develop AAV-based gene therapies for severe CNS diseases.
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Taysha Gene Therapies Inc (TSHA), detailing its revenue breakdown, profitability margins, and a comparison with competitors like WVE and GLUE. TSHA maintains a 100% gross margin but shows negative operating and net margins, indicating challenges in converting operational activities into shareholder value. The company has a market capitalization of $1.26 billion.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant to four new employees, involving restricted stock units representing 300,000 shares and an option to purchase 92,400 shares of common stock. This grant was made under the 2023 Inducement Plan as an essential part of their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs and stock options will vest over four years, subject to continued employment.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant to four new employees, consisting of restricted stock units (RSUs) representing 300,000 shares and options to purchase 92,400 shares of common stock. These grants were made under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to incentivize the employees to join the company. The RSUs and stock options have multi-year vesting schedules, contingent on continued employment.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced an inducement grant to four new employees on April 1, 2026, consisting of 300,000 restricted stock units and options to purchase 92,400 shares of common stock. This grant, made under the 2023 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), is intended to incentivize the new hires. The RSUs and stock options will vest over four years, subject to continued employment, with the stock option having an exercise price of $4.31.
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA
SG Americas Securities LLC significantly increased its stake in Taysha Gene Therapies by 2,271.8% in Q4, acquiring 748,525 shares to own a total of 781,474 shares valued at $4.3 million. Despite substantial insider selling and a trading down of shares, Taysha Gene Therapies beat its recent quarterly earnings estimates and holds an average "Buy" rating from analysts with an average price target of $11.09.
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA
Hennion & Walsh Asset Management Inc. has initiated a new position in Taysha Gene Therapies, Inc., acquiring 308,457 shares valued at approximately $1.70 million. This investment comes as Taysha Gene Therapies exceeded Q4 earnings expectations and reported strong revenue, with analysts maintaining a "Buy" consensus and an average price target of $11.09. Despite notable insider selling, institutional investors hold a significant stake in the company.
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances
Taysha Gene Therapies is advancing its pivotal clinical trial for TSHA-102, a gene therapy for Rett syndrome, with patient enrollment progressing. The company has outlined a plan for a Biologics License Application (BLA) submission in 2026 to the FDA, following discussions and encouraging interim data. This strategy aims to bring the potential treatment to patients sooner by leveraging existing data.
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial
Truist Financial has upgraded Taysha Gene Therapies (NASDAQ:TSHA) to a "strong-buy" rating. Despite recent insider sales totaling $2.82 million over 90 days, the company reported stronger-than-expected revenue and an EPS beat for the last quarter. The average price target from analysts for Taysha Gene Therapies is $11.09, with a consensus "Buy" rating.
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19
Cantor Fitzgerald has reiterated its Buy rating for Taysha Gene Therapies (TSHA.US) and maintained its target price at $19. This indicates a continued positive outlook from the firm regarding Taysha Gene Therapies' stock performance.
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9% - Time to Sell?
Taysha Gene Therapies (NASDAQ:TSHA) saw its stock price decline by 6.9% on Tuesday, trading down to about $4.23 with only 1.14 million shares traded. Despite this dip and recent insider selling totaling $2.82 million, analysts maintain a "Moderate Buy" consensus rating with a target price of $11.09. The company recently beat EPS and revenue estimates, though it remains loss-making, and institutional investors have shown mixed activity, adding to or reducing their stakes.
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus
Taysha Gene Therapies (TSHA) has received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome, reporting a 100% patient response rate in early data. The company is preparing for commercialization, with key regulatory and clinical milestones supporting its equity story, despite recent stock price declines against a strong longer-term performance. Taysha is currently flagged as undervalued by Simply Wall St, trading significantly below analyst targets, and its clinical progress is shifting investor focus from past financials to pipeline execution.
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts
Taysha Gene Therapies (NASDAQ:TSHA) has received a 'Moderate Buy' consensus rating from analysts, with 10 out of 12 firms issuing 'Buy' or 'Strong Buy' recommendations. The clinical-stage biotech focuses on gene therapies for rare CNS disorders, and analysts project an average 12-month price target of $11.09, citing positive Q4 2025 results and upcoming pivotal trial milestones for its lead program, TSHA-102. Despite development risks, analysts are optimistic about the company's pipeline.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average one-year target price of $11.09. This sentiment is driven by the company's Q4 2025 results that exceeded expectations and the on-track progress of its pivotal TSHA-102 trial, with a BLA submission anticipated in 2026. Despite insider stock sales and unprofitability, institutional ownership remains high, indicating investor confidence in its pipeline and strong cash position.
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies reported its full-year 2025 financial results and provided a corporate update on its TSHA-102 program for Rett syndrome. Key updates include dosing multiple patients in the REVEAL pivotal trial and receiving FDA clearance for the ASPIRE trial, both on track for Q2 2026 dosing completion. The company also announced written FDA alignment on manufacturing strategy for TSHA-102, supporting its planned BLA submission.
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation
Chardan Capital has reiterated its Buy rating on Taysha Gene Therapies (TSHA). While no specific price target was provided in this brief update, the maintained Buy recommendation suggests that Chardan Capital sees continued potential in the company.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies (NASDAQ: TSHA) announced its Q4 2025 financial results, reporting beating earnings expectations with an EPS of $-0.08711 against an expectation of $-0.09561. The company highlighted significant progress in the development of TSHA-102 for Rett syndrome, including FDA Breakthrough Therapy designation and alignment on pivotal trial designs, with dosing for the REVEAL pivotal and ASPIRE trials expected to be completed in 2026. Taysha Gene Therapies outlined a strong commercial opportunity for TSHA-102, citing high anticipated clinician and caregiver demand, particularly for its intrathecal administration which broadens patient access.
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC
Needham & Company LLC has increased its price target for Taysha Gene Therapies (NASDAQ:TSHA) from $10.00 to $12.00, maintaining a "buy" rating and implying a 163% upside. This adjustment follows positive clinical progress in the REVEAL pivotal trial for TSHA‑102, which is on track for completion and a 2026 BLA submission. Despite insider sales and the company's current unprofitability, its strong cash position is expected to support near-term trial execution.
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative
Taysha Gene Therapies reported a Q4 loss of US$27.9 million and a full-year net loss of US$109 million, highlighting the company's significant investment phase. Despite strong revenue growth expectations and the potential of its TSHA-102 program, profitability remains years away. The stock trades significantly below its fair value, but both bullish and bearish scenarios rely on highly optimistic future growth and earnings swings.
Rett syndrome gene therapy wins FDA clearance for child study, keeps Q2 timeline
Taysha Gene Therapies reported its full-year 2025 financial results and provided a corporate update, highlighting significant progress for its Rett syndrome gene therapy, TSHA-102. Key milestones include FDA clearance to initiate the ASPIRE trial for younger children, multiple patients dosed in the REVEAL pivotal trial, and positive FDA alignment on manufacturing strategy. Despite an increased net loss and R&D expenses, the company maintains a strong cash position that is expected to fund operations into 2028.
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory Plans - News and Statistics
Taysha Gene Therapies Inc. held a conference call on March 19, 2026, to discuss the development and regulatory plans for its product candidate TSHA-102. The company outlined its research and development strategies, including the timing for new clinical trials, data reporting, and engagement with the FDA for regulatory approval, specifically noting the potential for Breakthrough Therapy designation. The call also touched on the commercial prospects of TSHA-102, its potential to generate long-term stockholder value, and future financial outlook, while cautioning about inherent risks detailed in SEC filings.
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss
Taysha Gene Therapies reported a widened net loss of $109.0 million for the full year 2025, compared to $89.3 million in 2024, despite a 6.52% premarket stock uptick. The company is advancing its TSHA-102 gene therapy for Rett syndrome, with positive trial results and FDA alignment on a streamlined BLA submission pathway. Taysha maintains a strong cash position, expecting to fund operations into 2028, and is building commercial infrastructure for TSHA-102's potential launch.
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative
Taysha Gene Therapies (TSHA) reported a Q4 basic EPS loss of US$0.08 and a full-year trailing EPS loss of US$0.34, with ongoing net losses. Despite analysts' optimistic revenue growth projections, profitability is not expected for the next three years, raising questions about the feasibility of bullish scenarios tied to the TSHA-102 program. The company's current share price is significantly below fair value and analyst targets, but even bearish models rely on substantial future growth and profitability swings, while its 5.1x Price-to-Book ratio, dilution, and insider selling further complicate its investment profile.
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS
Taysha Gene Therapies reported $9.8 million in revenue for the year, primarily from Astellas-related transactions, with a widened net loss of $109.0 million, or $(0.34) per share, due to increased R&D and G&A spending. The company highlighted clinical milestones for REVEAL Part A, the initiation of the pivotal REVEAL Part B trial, and progress in the ASPIRE study to obtain pediatric safety data. Taysha is also scaling up its R&D and manufacturing to support clinical programs and potential commercialization.
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies, Inc. reported its full-year 2025 financial results and provided a corporate update, highlighting significant progress in the clinical development of TSHA-102 for Rett syndrome. The company successfully dosed multiple patients in its pivotal REVEAL trial and received FDA clearance for the ASPIRE trial, with both studies on track to complete dosing in Q2 2026. Taysha also reached written FDA alignment on manufacturing and regulatory strategies, reinforcing a clear path toward potential BLA submission and commercialization.
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies reported its full-year 2025 financial results and provided a corporate update, highlighting significant progress in the development of TSHA-102 for Rett syndrome. The company successfully dosed multiple patients in its REVEAL pivotal trial and received FDA clearance to initiate the ASPIRE trial, aiming for broad label inclusion in its BLA submission. Taysha also emphasized the favorable tolerability profile of TSHA-102 and strong commercial potential, projecting its current cash resources to fund operations into 2028.
Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation
Needham has reiterated its Buy recommendation for Taysha Gene Therapies (TSHA). While the firm maintained its Buy rating, it did not provide an updated price target in this communication. This suggests continued confidence in Taysha Gene Therapies' prospects despite no new valuation specified.
Needham Maintains Taysha Gene Therapies (TSHA) Buy Recommendation
Needham has reiterated its Buy recommendation for Taysha Gene Therapies (TSHA). This indicates a continued positive outlook from the analyst firm regarding the company's prospects.
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
Ally Bridge Group NY LLC acquired 1,898,112 shares of Taysha Gene Therapies (NASDAQ:TSHA) in Q3, making it their 8th largest holding. Institutional ownership is high at 77.7%, with several funds increasing their stakes, while insiders, including CEO Sean P. Nolan, sold a collective 598,623 shares. Analysts have a "Moderate Buy" rating for TSHA with an average price target of $10.91, significantly higher than its current share price of $4.49.
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies, Inc. announced it will report its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The company, a clinical-stage biotechnology firm, focuses on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, including its lead program TSHA-102 for Rett syndrome.
Taysha Gene Therapies to Release Full-Year 2025 Financial
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced it will report its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company focuses on advancing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program TSHA-102 targeting Rett syndrome.
Gene therapy biotech Taysha plans March 19 webcast on 2025 financial results
Taysha Gene Therapies (Nasdaq: TSHA) announced it will report its full-year 2025 financial results and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM ET. Investors can access the live webcast and archived replay via the company’s Events and Presentations page. This announcement sets the timetable for the results, with previous updates highlighting the company's progress with its Rett syndrome program (TSHA-102) and a strong cash position.
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies, Inc. announced it will release its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company, focused on gene therapies for severe monogenic diseases of the central nervous system, will provide access to the live webcast and an archived replay on its website.
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies (Nasdaq: TSHA) announced it will release its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company focuses on AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead program TSHA-102 targeting Rett syndrome. An archived replay of the webcast will be available on the company's website.
TSHA SEC Filings - Taysha Gene Therapies, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Taysha Gene Therapies (TSHA) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports. It highlights recent filings detailing BlackRock's passive stake, equity awards to Taysha's CFO and CEO, insider stock transactions, amendments to the company's ATM equity program, and significant progress for its TSHA-102 Rett syndrome program, including FDA Breakthrough Therapy designation and regaining full rights. The platform also offers AI-powered summaries of these lengthy filings for investor convenience.
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Taysha Gene Therapies (TSHA) announced the grant of restricted stock units and stock options to a new employee on March 2, 2026, as an inducement in connection with their employment, pursuant to Nasdaq Listing Rule 5635(c)(4). The grants comprise 156,870 restricted stock units and an option to purchase 134,460 shares, with vesting schedules tied to continued service. The stock option's exercise price is $4.53, matching the closing price on the grant date.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Taysha Gene Therapies announced an inducement grant in accordance with Nasdaq Listing Rule 5635(C)(4). The brief report, sourced from Refinitiv via Reuters, indicates this development relates to Taysha Gene Therapies (TSHA) management.
New Taysha hire granted 156,870 RSUs plus 134,460 options
Taysha Gene Therapies (Nasdaq: TSHA) announced that its Compensation Committee granted inducement awards to two new employees on March 2, 2026. The awards include 156,870 Restricted Stock Units (RSUs) and options to purchase 134,460 shares at an exercise price of $4.53, both vesting over four years subject to continued service. This grant was made under the 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced an inducement grant to a new employee on March 2, 2026. The grant, made under Nasdaq Listing Rule 5635(c)(4), includes restricted stock units representing 156,870 shares and an option to purchase 134,460 shares of common stock. These incentives are part of the employee's compensation package and are subject to vesting schedules tied to continued service.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced an inducement grant to a new employee on March 2, 2026, comprising RSUs for 156,870 shares and options for 134,460 shares of common stock. This grant falls under the Company’s 2023 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4), and is designed to attract new talent. Both the RSUs and stock options have multi-year vesting schedules contingent upon continued employment.
Taysha Gene faces earnings test as Rett trial advances
Taysha Gene Therapies Inc. is preparing to report fourth-quarter results, facing investor scrutiny over deepening losses against the backdrop of progress in its Rett syndrome gene therapy program, TSHA-102. Analysts predict a Q4 loss of 9.6 cents per share on revenue of $2.22 million, with all 14 analysts maintaining a "Strong Buy" rating and a mean price target implying a 143% upside. The company's cash runway and regulatory updates on its breakthrough-designated therapy will be key focuses, especially as the pivotal REVEAL trial advances.
Insider sale activity at Taysha Gene Therapies (NASDAQ: TSHA)
Taysha Gene Therapies (NASDAQ: TSHA) insider, Rumana Haque-Ahmed, submitted a Form 144 indicating plans to sell Common Stock shares related to a vested RSU award. The filing also disclosed previous sales by the reporting person totaling 31,337 shares across three transactions in January and February 2026, generating over $147,000 in proceeds. The RSU award vested on February 27, 2026, as consideration for continued service.
Taysha Gene Therapies, Inc. (TSHA): Analyst Ratings Signal Potential 140% Upside In Biotech Stock
Taysha Gene Therapies, Inc. (TSHA) is gaining investor attention due to analysts projecting a 140.70% potential upside. The clinical-stage biotech company focuses on developing gene therapies for monogenic central nervous system diseases, with promising candidates like TSHA-120 and TSHA-102. Despite current financial challenges including negative earnings and free cash flow, strong analyst confidence and an innovative pipeline make it a compelling, albeit risky, investment in the biotech sector.
TSHA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for TSHA, detailing past quarterly results and future forecasts. It highlights analyst estimates for upcoming quarters, revenue and EPS revisions, and the correlation between these revisions and stock price movements. The piece also examines TSHA's historical stock price reactions before and after earnings reports, offering insights for investors.
TSHA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Taysha Gene Therapies, Inc. (TSHA), including its income statement, balance sheet, and cash flow statement, derived from SEC filings. While the company exhibits strong liquidity and low leverage, it faces significant challenges with profitability, revenue decline, and negative cash flow, resulting in a weak overall financial health score.
